Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine and Gemcitabine in Second-Line NSCLC
NCT00077350Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2004
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triapine in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 1.5 years. Started Jul 2004; status: completed.
02
Drugs
triapine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00077350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077350.